target="_blank">IMDRF SaMD guidance, which outlines the risk classification and regulatory pathways for SaMD products.

It is crucial for developers and manufacturers of SaMD to understand the levels of risk associated with their software. The three levels of risk are:

• Low Risk (Class I): Minimal regulatory control needed.
• Moderate Risk (Class II): Special controls applied.
• High Risk (Class III): Premarket approval required.

Each classification impacts the development, testing, and post-market surveillance obligations and should inform the organization’s overall regulatory strategy.

Key Components of the FDA SaMD Policy

The FDA SaMD policy consists of several components that are crucial for compliance and successful commercialization.

1. Risk-Based Classification

As previously noted, the risk-based classification system helps distinguish the level of controls necessary for different SaMD products. This aligns with the TPCL approach (Total Product Lifecycle), advocating that regulatory oversight should extend beyond premarket evaluation to encompass post-market surveillance and real-world use.

2. Pre-market Submission Types

Before bringing a SaMD product to market, companies must determine the appropriate premarket submission type. The FDA SaMD framework identifies several pathways:

• 510(k) Notifications: For devices that are substantially equivalent to a legally marketed predicate.
• PMA (Premarket Approval): For high-risk devices requiring robust clinical evidence.
• De Novo Classification: For novel devices not previously classified, allowing a pathway to market for lower-risk devices.

3. Design Controls

Design controls are essential to demonstrate that the SaMD product meets user needs and intended uses. Adopting practices from 21 CFR Part 820 ensures that quality is built into the development process.

4. Post-Market Surveillance

Once on the market, the obligation to monitor the software’s performance continues. Post-market requirements can include collecting user feedback, monitoring adverse events, and conducting studies to ensure the ongoing safety and effectiveness of the software.

Emerging Trends in FDA SaMD Policy

With technological advancements, the FDA is continually adapting its SaMD framework. Recognizing these emerging trends is crucial for compliance. We will outline key trends that influence the regulatory landscape for AI-driven software.

1. Artificial Intelligence and Machine Learning Integration

The incorporation of AI and machine learning (ML) in SaMD introduces challenges and opportunities in regulatory oversight. AI-driven SaMD requires a robust framework to address issues related to algorithm changes, learning patterns from real-world data and ensuring that the software meets its intended use continuously.

The FDA has recognized these challenges and proposed guidelines to accommodate AI/ML updates through a pre-submission process that facilitates stakeholder discussions, ensuring that the evolving technology can be evaluated without compromising patient safety.

2. Patient-Centric Design Enhancements

Patient-centric designs are becoming increasingly relevant as the FDA emphasizes inclusivity and usability in SaMD. This development aligns with global trends aiming to enhance patient engagement during the design and testing phase. Human factors engineering principles must be integrated early in the development process to minimize errors and streamline usage.

3. Regulatory Harmonization with Global Standards

As SaMD increasingly crosses borders, regulatory harmonization becomes critical. The FDA collaborates with international partners, including the International Medical Device Regulators Forum (IMDRF), to align SaMD regulations. Adopting similar frameworks across different regions will ease the market entry for SaMD products globally.

Developing a Regulatory Strategy for AI-Driven SaMD

When developing a regulatory strategy for AI-driven SaMD, it is imperative to consider several key elements that will facilitate compliance.

1. Early Engagement with the FDA

Engaging with the FDA early in the development process can be advantageous. The FDA’s Q-Submission program allows developers to request feedback on specific design and testing elements, enabling them to adapt their strategies based on preliminary guidance.

2. Comprehensive Risk Management Plan

A risk management plan should be comprehensive and encompass every stage of the software lifecycle. Utilizing ISO 14971, manufacturers can ensure that risks are identified, assessed, and mitigated effectively.

3. Clinical Evaluation of AI-Driven Software

For AI-driven SaMD, the clinical evaluation must reflect how the software performs in real-world scenarios. This evaluation can contribute to the body of evidence supporting the software’s safety and efficacy, aligning with the TPCL approach.

Considerations for Quality Systems and Compliance

Whether developing software as a standalone application or as part of a broader medical device, quality systems underpin successful FDA compliance. Adopting a structured approach, aligned with the regulatory framework, is essential for all stakeholders involved.

1. Implementing Design Controls

Design controls are paramount in the FDA SaMD framework. Components include design input verification, design output validation, and design review processes, ensuring the software meets both regulatory and user needs.

2. Quality Management Systems (QMS)

Integrating quality management systems that comply with 21 CFR Part 820 will ensure that the organization can systematically address quality issues throughout the product lifecycle. A well-structured QMS can also streamline interaction with FDA during audits and inspections.

Conclusion: Preparing for the Future of SaMD Regulation

The FDA’s trajectory for SaMD regulation signifies an evolving landscape shaped by innovative technologies, notably AI. Adapting to these changes requires a proactive approach, emphasizing the pillars of patient safety, robust design controls, and persistent engagement with regulatory bodies. As digital health, regulatory, clinical, and quality leaders navigate these trends, aligning strategies with the FDA SaMD framework will be essential for success in this dynamic field.

In a world that increasingly values health data and digital interventions, understanding the FDA’s expectations is pivotal for those involved in the development of SaMD, apps, and AI solutions.